Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals

References

• Ele F, Andrea M. β-Cell function in type 2 diabetes. Metabolism. 2014;63:1217–1227.
   PubMed Web of Science ®Google Scholar
• Xu Y. Prevalence and control of diabetes in Chinese Adults. Jama. 2013;310:948–959.
   PubMed Web of Science ®Google Scholar
• Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660–671.
   PubMed Web of Science ®Google Scholar
• Li K, Zhai M, Jiang L, et al., Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway, Oxid. Med. Cell. Longev., 2019 ( 2019) 6746907.
   Google Scholar
• Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17:20–33.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen L, Wu H, et al. Protective effect of glucagon-like peptide-1 mediated by ultrasound microbubbles on myocardial injury in rats with diabetic cardiomyopathy. Bioengineered. 2022;13:3251–3261.
   PubMed Web of Science ®Google Scholar
• Evangelista I, Nuti R, Picchioni T, et al. Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy. Int J Mol Sci. 2019;20:3264.
   PubMed Web of Science ®Google Scholar
• Dillmann WH. Diabetic cardiomyopathy, circ. Res. 2019;124:1160–1162.
   Google Scholar
• Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61:21–28.
   PubMed Web of Science ®Google Scholar
• Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials, Postgrad. Med J. 2020;96:156–161.
   Google Scholar
• Hitman GA, Leslie RD, Holt RIG. GLP-1-based diabetes therapies; trial by media. Diabet Med. 2013;30:1147.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15–30.
   PubMed Web of Science ®Google Scholar
• Dhanwantee M, Alison C-V, Mansoor H. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9:95–108.
   PubMed Web of Science ®Google Scholar
• Laurie L, Baggio A, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Hansotia T, Drucker D. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept. 2005;128:125–134.
   PubMed Web of Science ®Google Scholar
• Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Practice & Research Clinical Endocrinology & Metabolism (abbreviation: Best Pract Res Clin Endocrinol Metab). 2009;23:443–452.
   PubMed Web of Science ®Google Scholar
• Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221:T31–41.
   PubMed Web of Science ®Google Scholar
• Zhang ZQ, Hölscher C. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides. 2020;125:170184.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Kahn BB, Rosen AS, Bak JF, et al. Expression of GLUT1 and GLUT4 glucose transporters in skeletal muscle of humans with insulin-dependent diabetes mellitus: regulatory effects of metabolic factors. J Clin Endocrinol Metab. 1992;74:1101–1109.
   PubMed Web of Science ®Google Scholar
• Jurysta C, Nicaise C, Giroix MH, et al. Comparison of GLUT1, GLUT2, GLUT4 and SGLT1 mRNA expression in the salivary glands and six other organs of control, streptozotocin-induced and Goto-Kakizaki diabetic rats, Cell. Physiol Biochem. 2013;31:37–43.
   Google Scholar
• Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol. 2002;283:H976–H982.
   PubMed Web of Science ®Google Scholar
• Qi B, He L, Zhao Y, et al. Akap1 deficiency exacerbates diabetic cardiomyopathy in mice by NDUFS1-mediated mitochondrial dysfunction and apoptosis. Diabetologia. 2020;63:1072–1087.
   PubMed Web of Science ®Google Scholar
• Sung MM, Hamza SM, Dyck JR. Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets, Antioxid. Redox Signal. 2015;22:1606–1630.
   PubMed Web of Science ®Google Scholar
• Davargaon RS, Sambe AD, Muthangi VVS. Toxic effect of high glucose on cardiomyocytes, H9c2 cells: Induction of oxidative stress and ameliorative effect of trolox. J Biochem Mol Toxicol. 2019;33:e22272.
   PubMed Web of Science ®Google Scholar
• Bertram R, Gram Pedersen M, Luciani DS, et al. A simplified model for mitochondrial ATP production. J Theor Biol. 2006;243:575–586.
   PubMed Web of Science ®Google Scholar
• Tan Y, Zhang Z, Zheng C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585–607.
   PubMed Web of Science ®Google Scholar
• Davidson SM, Adameová A, Barile L, et al. Mitochondrial and mitochondrial-independent pathways of myocardial cell death during ischaemia and reperfusion injury. J Cell Mol Med. 2020;24:3795–3806.
   PubMed Web of Science ®Google Scholar
• Estaquier J, Vallette F, Vayssiere JL, et al. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157–183.
   PubMed Web of Science ®Google Scholar
• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity, circ. Res. 2018;122:624–638.
   Google Scholar
• Ye L, Chen X, Wang M, et al. Curcumin analogue C66 attenuates obesity-induced myocardial injury by inhibiting JNK-mediated inflammation. Biomed Pharmacother. 2021;143:112121.
   PubMed Web of Science ®Google Scholar
• Chen K, Li G, Geng F, et al. Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats. Apoptosis. 2014;19:946–957.
   PubMed Web of Science ®Google Scholar
• Carling D. AMPK signalling in health and disease, curr. Opin Cell Biol. 2017;45:31–37.
   PubMed Web of Science ®Google Scholar
• Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway, mol. Biosyst. 2015;11:1946–1954.
   Google Scholar